Skip to main content
Signal8

BriaCell Therapeutics Corp. (BCTXL)

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

BriaCell Therapeutics Corp. logo

BriaCell Therapeutics Corp.

NASDAQ:BCTXLSub-class of BCTXHealthcare
-2.44%$0.8000
CLOSED
Mkt Cap$6.99M
EV-
Float8.72M
O/S8.73M
VOL79K sh
$ Vol$63K
RVOL4.64×
Inst Own-
SI0.1%
Net Cash/Sh-
Dilution
BriaCell Therapeutics Corp. logoNASDAQ:BCTXLClosed$0.8000-2.44%
Pipeline4 lead-sponsored trials·1 active2 completed

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 3
    Recruiting

    Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    SV-BR-1-GM, Cyclophosphamide

    Breast Cancer, Metastatic Breast Cancer +3

    Enrollment
    404
    Start
    Dec 2023
    Primary Completion
    Dec 2027est.
    Completion
    Jun 2028est.
    NCT06072612
  • Phase 1/2
    Completed

    SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

    SV-BR-1-GM, Cyclophosphamide

    Breastcancer, Breast Neoplasm

    Enrollment
    24
    Start
    May 2017
    Primary Completion
    Nov 2018
    Completion
    Nov 2018
    NCT03066947
  • Phase 1/2
    Completed

    Combination Study of SV-BR-1-GM With Retifanlimab

    SV-BR-1-GM, Low dose cyclophosphamide

    Breast Cancer, Breast Neoplasm +2

    Enrollment
    36
    Start
    Mar 2018
    Primary Completion
    Mar 2026
    Completion
    Mar 2026
    NCT03328026
  • Phase 1/2
    Unknown status

    A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

    BC1 cell line, Bria-OTS regimen and CPI (tislelizumab)

    Breast Cancer, Breast Tumor +4

    Enrollment
    18
    Start
    May 2024
    Primary Completion
    Apr 2025est.
    Completion
    Oct 2025est.
    NCT06471673